But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

although it will compete with Allergan's older Restasis (cyclosporin). The US Food and Drug Administration initially rejected Xiidra in October last year, asking for an additional study.